Previsioni

Il prezzo obiettivo medio degli analisti è 86,58 € (+36,35%). La mediana è 86,58 € (+36,35%).

Acquista
  10
Mantieni
  2
Vendi
  0

Discussioni nella community

Non ci sono ancora discussioni su questo asset.

Avvia discussione

  • RadNet beats Q2 forecasts and raises full-year guidance

    RadNet reported adjusted EPS of $0.29 for Q2 2026 on revenue of $622.7m, both well above consensus estimates, and posted an adjusted EBITDA quarterly record of $99.7m. Total revenue rose 25% year over year, driven by stronger demand for advanced imaging and a 56.5% increase in digital-health revenue; ARR nearly doubled to $105.5m. The company raised its full-year targets for imaging revenue, adjusted EBITDA and free cash flow. The stock rose about 6% in after-hours trading, while management highlighted accelerated adoption of AI solutions and continued wage-pressure and integration risks. » Altro su de.investing.com


  • RadNet secures $250 million loan and lowers interest costs

    RadNet has amended its existing credit agreement and taken on an additional $250 million loan, which is being combined with the existing facility (totaling $1.2087 billion) and matures on April 18, 2031. Quarterly principal payments will rise from $2.4 million to about $3.1 million. RadNet plans to use the funds for acquisitions, organic growth, healthcare partnerships and general corporate purposes. The interest rate has been cut by 0.25 percentage points (choice of Term SOFR plus 2.00% or an alternate base rate plus 1.00%), and the terms of the revolving credit line were also improved, strengthening the company’s financial flexibility with a cash position of $455 million as of March 31, 2026. » Altro su de.investing.com


  • DeepHealth (RadNet subsidiary) launches AI platform Reporting Pro for radiology reporting

    DeepHealth, a wholly owned subsidiary of RadNet, has made Reporting Pro commercially available — an AI-powered platform for creating radiology reports that combines speech recognition, clinical AI findings, measurements, generative AI assessments, and quality assurance in a single workflow. The solution incorporates both FDA-cleared and CE-marked AI tools, can integrate with existing PACS/RIS systems, and supports all imaging modalities. RadNet is rolling out Reporting Pro across its own network, has secured initial external customers, and plans to expand into additional countries by the end of the year. » Altro su de.investing.com


  • Moody's cuts rating of RadNet's senior secured bank credit facilities after $200m loan

    Moody’s downgraded RadNet’s senior secured bank credit facilities from Ba3 to B1; the Corporate Family Rating remains at B1 with a stable outlook. The downgrade follows the issuance of an additional $200 million senior loan to finance acquisitions and expansion, which raises pro forma leverage from about 4.5x to around 5.0x. Moody’s cites higher fixed costs and geographic concentration as pressure points, but highlights RadNet’s strong competitive position, revenue diversification and a pro forma liquidity position of more than $600 million, and expects leverage to decline over the next 12–18 months. » Altro su de.investing.com


  • RadNet beats revenue forecasts in Q1 2026, stock rises despite EPS miss

    RadNet reported Q1 2026 revenue of $575.63 million versus $557.64 million expected (+3.23% surprise) with EPS of $-0.28 (forecast -$0.15). Revenue rose 22.1% year over year, adjusted EBITDA increased 36.3%, and days sales outstanding (DSO) were 29.5 days. The stock climbed 8.95% in premarket trading to $63.40 as investors reacted positively to revenue growth, digital health initiatives and acquisition contributions. RadNet maintains an upbeat outlook with FY 2026 guidance of $0.63 EPS and expected revenues of $2.45 billion. » Altro su de.investing.com

Dati finanziari

Nell'ultimo trimestre, RadNet ha registrato ricavi pari a 563,49 Mln € e un utile netto di 3,67 Mln €

(EUR) settembre 2026
YoY
Ricavi 563,49 Mln 26,47%
Utile lordo 75,81 Mln 22,74%
Utile netto 3,67 Mln 20,57%
EBITDA 84,05 Mln 27,39%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
5 Mld €
Numero di azioni
78,77 Mln
Massimo/minimo a 52 settimane
78,23 € - 46,31 €
Dividendi No
Beta
1,40
Rapporto P/E
-242,22
Rapporto PEG
3,65
Rapporto P/B
4,84
Rapporto P/S
2,30

Profilo aziendale

RadNet, Inc., insieme alle sue controllate, fornisce servizi di diagnostica per immagini ambulatoriale negli Stati Uniti. I suoi servizi comprendono la risonanza magnetica, la tomografia computerizzata, la tomografia a emissione di positroni, la medicina nucleare, la mammografia, l'ecografia, la radiologia diagnostica, la fluoroscopia e altre procedure correlate, nonché servizi di imaging multimodale. La società sviluppa e commercializza anche sistemi informatici per l'industria della diagnostica per immagini, tra cui sistemi di archiviazione e comunicazione delle immagini (PACS) e servizi correlati; sviluppa e implementa suite di intelligenza artificiale per migliorare l'interpretazione delle immagini da parte dei radiologi nel campo della mammografia, nonché soluzioni di intelligenza artificiale per il cancro al polmone e alla prostata. Al 31 dicembre 2021 gestiva di proprietà 347 centri in Arizona, California, Delaware, Florida, Maryland, New Jersey e New York. La società è stata fondata nel 1981 ed ha sede a Los Angeles, California.

Nome
RadNet
CEO
Howard G. Berger
Sede centrale Los Angeles, ca
Stati Uniti
Sito web
Settore
Sanità
Industria
Attrezzature e forniture sanitarie
Quotazione in borsa
10/12/2021
Dipendenti 9060

Simboli di borsa

Borsa Simbolo
NASDAQ
RDNT
Frankfurt
PQIA.F
Düsseldorf
PQIA.DU
SIX
PQIA.SW
🍪

Parqet  usa i cookie. Scopri di più